Onvansertib cut the risk of death or disease progression by 62% versus standard of care, but analysts await more detailed ...

Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in ...

Onvansertib combined with FOLFIRI and Avastin shows dose-dependent improvements in tumor response and disease control for RAS ...

Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a median progression-free survival of 9.2 months. The study highlighted notable ...

Cardiff Oncology (NASDAQ:CRDF) outlined a management transition and provided an updated clinical data readout for onvansertib during a company conference call focused on its ongoing Phase II CRDF-004 ...

– 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) “Petosemtamab’s unique mechanism of ...

- Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and a manageable safety profile UTRECHT, The Netherlands and ...

Phase 1b study to assess the safety of neoadjuvant trifluridine/tipiracil with concurrent radiation in resectable stage II/III rectal cancer. This is an ASCO Meeting Abstract from the 2023 ASCO ...

In the evolving landscape of metastatic colorectal cancer, managing patients with RAS/BRAF wild-type tumors remains a ...